Xxgiaxxs LXX Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Xxgiaxxs LXX Pharmaceutical Import Records from India — 2 Products, $1.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Xxgiaxxs LXX — Pharmaceutical Importer Profile (2026) | 2 Products, $1.3M Trade | TransData Nexus

Xxgiaxxs LXX

Pharmaceutical Importer · United States · Advanced Antibiotics Focus · $1.3M Total Trade · DGFT Verified

Xxgiaxxs LXX is a pharmaceutical importer based in United States with a total trade value of $1.3M across 2 products in 2 therapeutic categories. Based on 25 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Xxgiaxxs LXX sources from 1 verified Indian supplier, with Ms Eugia Sez Private Limited accounting for 100.0% of imports.

Xxgiaxxs LXX — Import Portfolio & Supplier Network

Xxgiaxxs LXX import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Xxgiaxxs LXX?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Ms Eugia Sez Private Limited	$1.3M	25	100.0%

Xxgiaxxs LXX sources from 1 verified Indian supplier across 5 distinct formulations. The sourcing is highly concentrated — Ms Eugia Sez Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Xxgiaxxs LXX Import?

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Piperacillin	Advanced Antibiotics	$650.0K	13	0.7%	8
2	Ampicillin	Antibiotics	$600.0K	12	0.4%	11

Xxgiaxxs LXX imports 2 pharmaceutical products across 2 categories into United States totaling $1.3M.

Xxgiaxxs LXX — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Xxgiaxxs LXX is a United States-based pharmaceutical importer specializing in the procurement of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company plays a pivotal role in the U.S. pharmaceutical distribution network by sourcing and importing these formulations to meet domestic demand. While specific details about its headquarters and parent company are not publicly disclosed, Xxgiaxxs LXX's operations are integral to the supply chain, ensuring the availability of essential medications within the United States.

2Distribution Network

Xxgiaxxs LXX's distribution network encompasses multiple warehouse locations strategically positioned across the United States to facilitate efficient logistics and timely delivery of pharmaceutical products. The company's logistics capabilities are robust, enabling it to manage a diverse portfolio of imported formulations. Geographically, Xxgiaxxs LXX's coverage spans the entire U.S., ensuring that its products are accessible to a wide range of healthcare providers and patients nationwide.

3Industry Role

In the U.S. pharmaceutical supply chain, Xxgiaxxs LXX functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from international suppliers, the company bridges the gap between foreign manufacturers and the U.S. market, ensuring that a variety of medications are available to meet domestic healthcare needs. This role is crucial in maintaining the flow of pharmaceutical products and supporting the overall healthcare infrastructure in the United States.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Xxgiaxxs LXX

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Xxgiaxxs LXX demonstrates a high degree of sourcing concentration, importing a total of $1.3 million worth of pharmaceutical products from a single supplier, MS EUGIA SEZ PRIVATE LIMITED, across 25 shipments. This single-source dependency indicates a strategic choice to establish a focused and potentially more efficient supply chain relationship. The consistent volume and frequency of shipments suggest a stable and reliable partnership, which can lead to favorable terms and streamlined logistics. However, this concentration also exposes Xxgiaxxs LXX to risks associated with supplier dependency, such as potential disruptions in supply due to issues at the supplier's end.

2Supply Chain Resilience

The resilience of Xxgiaxxs LXX's supply chain is closely tied to the stability and reliability of its sole supplier, MS EUGIA SEZ PRIVATE LIMITED. While the concentrated sourcing strategy may offer operational efficiencies, it also means that any disruptions at the supplier's facility could significantly impact Xxgiaxxs LXX's ability to meet market demand. The lack of backup suppliers and limited formulation diversity further heighten this vulnerability. Additionally, the supplier's shipping routes and regulatory compliance are critical factors that influence the overall resilience of the supply chain.

Strategic Implications

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which prohibits the interstate shipment of unapproved new drugs. The FDA's regulations require that foreign drug establishments register with the agency and list all drugs intended for commercial distribution in the U.S. Additionally, imported drugs must comply with FDA standards to ensure they are not adulterated or misbranded.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. include the registration of foreign drug establishments with the FDA and the listing of all drugs intended for commercial distribution. Good Manufacturing Practice (GMP) certification is essential, with the FDA recognizing certifications from reputable authorities such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications to meet FDA standards. Additionally, wholesale distribution authorization is required to legally distribute pharmaceutical products within the United States.

Xxgiaxxs LXX — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Xxgiaxxs LXX's focus on importing advanced antibiotics and antibiotics aligns with the ongoing demand for these medications in the U.S. market. The therapeutic areas of advanced antibiotics and antibiotics constitute 52.0% and 48.0% of their portfolio, respectively, indicating a balanced approach to addressing various bacterial infections. The substantial import values of Piperacillin ($650K) and Ampicillin ($600K) reflect the critical role these antibiotics play in treating a wide range of infections, underscoring their market demand.

2Sourcing Profile

Xxgiaxxs LXX's sourcing strategy is centered on importing generic formulations from India, focusing on antibiotics. This approach leverages India's robust pharmaceutical manufacturing capabilities and cost advantages. By concentrating on finished pharmaceutical formulations, Xxgiaxxs LXX ensures that the products meet the FDA's stringent quality standards, facilitating smoother market entry and distribution within the United States.

3Market Positioning

Based on its product mix, Xxgiaxxs LXX serves the wholesale distribution segment of the U.S. pharmaceutical market. By importing and distributing essential antibiotics, the company supports various healthcare providers, including hospitals, clinics, and pharmacies, ensuring the availability of critical medications for patient care.

Seller's Guide — How to Become a Supplier to Xxgiaxxs LXX

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Xxgiaxxs LXX, particularly those offering high-quality, FDA-compliant finished pharmaceutical formulations. Suppliers that can provide a diverse range of antibiotics and other essential medications may find a receptive partner in Xxgiaxxs LXX. Identifying and addressing any gaps in Xxgiaxxs LXX's current sourcing, such as the need for additional formulations or alternative suppliers, could further strengthen this potential partnership.

2Requirements & Qualifications

Indian exporters seeking to supply Xxgiaxxs LXX and the U.S. market must ensure that their products are manufactured in facilities registered with the FDA and comply with recognized GMP standards, such as EU GMP, WHO GMP, or PIC/S certifications. Products must undergo batch testing to verify quality and stability, and labeling must meet FDA requirements, including English language specifications. Additionally, exporters should be prepared to provide necessary documentation and certifications to facilitate the importation process.

3How to Approach

Frequently Asked Questions — Xxgiaxxs LXX

What products does Xxgiaxxs LXX import from India?

Xxgiaxxs LXX imports 2 pharmaceutical products across 2 categories. Top imports: Piperacillin ($650.0K), Ampicillin ($600.0K).

Who supplies pharmaceuticals to Xxgiaxxs LXX from India?

Xxgiaxxs LXX sources from 1 verified Indian suppliers. The primary supplier is Ms Eugia Sez Private Limited (100.0% of imports, $1.3M).

What is Xxgiaxxs LXX's total pharmaceutical import value?

Xxgiaxxs LXX's total pharmaceutical import value from India is $1.3M, based on 25 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Xxgiaxxs LXX focus on?

Xxgiaxxs LXX imports across 2 categories. The largest: Advanced Antibiotics (52.0%), Antibiotics (48.0%).

Get Full Xxgiaxxs LXX Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Formulation	Value	Ships
Piperacillin & tazobactam	$650.0K	13
Ampicillin for	$350.0K	7
Ampicillin and	$150.0K	3
Ampicillin and sulbactam	$50.0K	1
Ampicillin and sulbactam for	$50.0K	1